Clues in SCAF, a DOAC antidote trial, another negative lytic trial in stroke, JAMA changes to observational studies, and BP in stroke care are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. ARTESIA Substudy

Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology 

https://www.medscape.com/viewarticle/998215

• ARTESIA Substudy
• NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
• ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234

II. DOAC Reversal

• ANNEXA-1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2313040

III. Lytic Therapy in Acute Stroke

Thrombolysis Offers No Benefit for Mild Stroke

https://www.medscape.com/viewarticle/iv-thrombolysis-offers-no-benefit-mild-stroke-2024a10009p7

• TEMPO-2 Trial https://doi.org/10.1016/S0140-6736(24)00921-8
• The Case Against Thrombolytic Therapy in Stroke

IV. Observational Research

• JAMA Special Communication https://jamanetwork.com/journals/jama/fullarticle/2818746
• JAMA editors note https://jamanetwork.com/journals/jama/fullarticle/2818747

V. Aggressive BP Control in Stroke

Guidelines on Rapid BP Reduction in Acute Ischemic Stroke Challenged

https://www.medscape.com/viewarticle/guidelines-rapid-bp-reduction-acute-ischemic-stroke-2024a10009pe

• TRUTH Trial  https://doi.org/10.1016/S1474-4422(24)00177-7

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]